Matching these considerations, a recent study comparing Sanger with NGS in breast cancer showed that the additional TP53 mutations detected by NGS had no additional impact on the clinical information that was already provided by Sanger sequencing [22]. The gene discussed is TP53; the disease is breast cancer.